---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009476"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:05:05.441587+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra reports positive Phase 2 top-line data for KP1077 in idiopathic hypersomnia

## Summary
- KP1077 showed clinically meaningful improvement in excessive daytime sleepiness on ESS, maintained through open-label and double-blind phases.
- Improvements also observed in IHSS, Sleep Inertia VAS, and Brain Fog severity scale at end of both open-label and double-blind periods.
- Drug was well-tolerated at all doses (up to 320 mg/day); most common AEs were insomnia, headache, anxiety, nausea, decreased appetite.
- Company plans to request end-of-Phase 2 meeting with FDA for guidance on Phase 3 trial design.
- Study enrolled 66 patients; 50 continued into double-blind phase; not powered for statistical significance.

## SEC filing metadata
- accession: 0001437749-24-009476
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924009476/0001437749-24-009476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924009476/zvra20240326_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009476
- JSON: https://secwatch.observer/filing/0001437749-24-009476.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.